| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 31.01.
| Nektar Therapeutics Shares Up 17.1% Since SmarTrend's Buy Recommendation | | 1 | SmarTrend |
| 23.01.
| Nektar Therapeutics: Often Forgotten, But Worth A Look | | 3 | Seeking Alpha |
| 20.01.
| Nektar Therapeutics Crosses Below its 10-day MA | | - | SmarTrend |
| 20.01.
| Shares of Nektar Therapeutics Under Pressure, Down 4.0% | | - | SmarTrend |
| 17.01.
| Possible Bearish Inside Day Candle Pattern Detected for Nektar Therapeutics | | 1 | SmarTrend |
| 13.01.
| A Forward Look, the Year Ahead -- Featured Research on Achillion Pharmaceuticals, Inc. and Nektar Therapeutics | | 36 | MarketWire |
| HONG KONG -- (Marketwire) -- 01/13/12 -- Today, www.BollingerReport.com introduced featured coverage of Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) and Nektar Therapeutics (NASDAQ: NKTR). Full...
Mehr lesen zu:
A Forward Look, the Year Ahead -- Featured Research on Achillion Pharmaceuticals, Inc. and Nektar Therapeutics | |
| 05.01.
| Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA | | 39 | PR Newswire |
| SAN FRANCISCO, Jan. 4, 2012 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming...
Mehr lesen zu:
Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA | |
| 13.12.
| Nektar Announces Positive Clinical Data from Second Phase 1 Clinical Study of NKTR-181, a Novel Opioid Analgesic Molecule to Treat Chronic Pain | | 18 | PR Newswire |
| SAN FRANCISCO, Dec. 13, 2011 /PRNewswire/ --Nektar Therapeutics (Nasdaq: NKTR) today announced positive data from a Phase 1 clinical study of NKTR-181 evaluating multiple ascending...
Mehr lesen zu:
Nektar Announces Positive Clinical Data from Second Phase 1 Clinical Study of NKTR-181, a Novel Opioid Analgesic Molecule to Treat Chronic Pain | |
| 12.12.
| Nektar Begins Phase 3 BEACON Trial Of NKTR-102 | | 25 | AFX News |
| WASHINGTON (dpa-AFX) - Nektar Therapeutics (NKTR) said it has initiated its
pivotal Phase 3 global clinical trial evaluating NKTR-102 as a single agent in
women with metastatic breast cancer....
Mehr lesen zu:
Nektar Begins Phase 3 BEACON Trial Of NKTR-102 | |
| 12.12.
| Nektar (NKTR) Initiates NKTR-102 Phase 3 in Women with Metastatic Breast Cancer | | - | StreetInsider.com |
| 12.12.
| Nektar Therapeutics Initiates Phase 3 BEACON Trial of NKTR-102 in Women with Metastatic Breast Cancer | | 28 | PR Newswire |
| SAN FRANCISCO, Dec. 12, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that the company has initiated its pivotal Phase 3 global clinical trial evaluating NKTR-102 as a single...
Mehr lesen zu:
Nektar Therapeutics Initiates Phase 3 BEACON Trial of NKTR-102 in Women with Metastatic Breast Cancer | |
| 08.12.
| Nektar Reports Affymax Announced FDA Advisory Committee Voted in Favor of Benefit/Risk Profile for Peginesatide for Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis | | 34 | PR Newswire |
| SAN FRANCISCO, Dec. 8, 2011 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported that its partner Affymax, Inc. announced that the U.S. Food and Drug Administration (FDA) Oncologic...
Mehr lesen zu:
Nektar Reports Affymax Announced FDA Advisory Committee Voted in Favor of Benefit/Risk Profile for Peginesatide for Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis | |
| 14.11.
| Nektar (NKTR) Reports Positive Preclinical Data for NKTR-192 | | 1 | StreetInsider.com |
| 14.11.
| Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011 | | 5 | PR Newswire |
| SAN FRANCISCO and WASHINGTON, Nov. 14, 2011 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today that positive preclinical data for NKTR-192, a novel mu-opioid agonist, was presented...
Mehr lesen zu:
Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011 | |
| 03.11.
| Nektar Therapeutics Q3 Loss Widens | | 49 | AFX News |
| WASHINGTON (dpa-AFX) - Nektar Therapeutics (NKTR) reported a net loss for
the third quarter of $24.1 million or $0.21 per share, compared to a net loss of
$8.7 million or $0.09 per share...
Mehr lesen zu:
Nektar Therapeutics Q3 Loss Widens | |
| 02.11.
| Nektar Therapeutics Reports Third Quarter 2011 Financial Results | | 16 | PR Newswire |
| SAN FRANCISCO, Calif., Nov. 2, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2011.
Cash, cash equivalents...
Mehr lesen zu:
Nektar Therapeutics Reports Third Quarter 2011 Financial Results | |
| 26.10.
| Nektar to Announce Financial Results for the Third Quarter of 2011 on Wednesday, November 2, 2011, After Close of U.S.-Based Financial Markets | | 16 | PR Newswire |
| SAN FRANCISCO, Oct. 26, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2011 on Wednesday, November 2, 2011, after...
Mehr lesen zu:
Nektar to Announce Financial Results for the Third Quarter of 2011 on Wednesday, November 2, 2011, After Close of U.S.-Based Financial Markets | |
| 26.10.
| Drug Approval Rate Stagnant -- Nektar and ADVENTRX Look to Defy Odds / The Paragon Report Provides Equity Research on Nektar Therapeutics & ADVENTRX Pharmaceuticals | | 22 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 10/26/11 -- Drug approvals from administrative bodies in both the U.S. and Europe have been pivotal for biotech companies recently. Investors have been particularly...
Mehr lesen zu:
Drug Approval Rate Stagnant -- Nektar and ADVENTRX Look to Defy Odds / The Paragon Report Provides Equity Research on Nektar Therapeutics & ADVENTRX Pharmaceuticals | |
| 21.09.
| Nektar (NKTR) Reports Strong Data from NKTR-181 Phase 1 | | 1 | StreetInsider.com |
| 21.09.
| Nektar Presents Positive Data for Novel Opioid Analgesic, NKTR-181, at the 2011 American Academy of Pain Management Annual Meeting | | 16 | PR Newswire |
| SAN FRANCISCO, Sept. 21, 2011 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that positive proof-of-concept data is being presented from its first Phase 1 clinical trial of NKTR-181...
Mehr lesen zu:
Nektar Presents Positive Data for Novel Opioid Analgesic, NKTR-181, at the 2011 American Academy of Pain Management Annual Meeting | |
